抗てんかん薬の世界市場：成長、将来の見通し、競合分析（2022年～2030年）

当レポートでは、世界の抗てんかん薬市場について調査分析し、市場動向、市場力学、セグメント別・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

• レポートの説明
  • レポートの目的
  • 対象者
  • 主要な製品
• 市場の内訳
• 調査手法
  • フェーズI：2次調査
  • フェーズII：1次調査
  • フェーズIII：専門家別審査
  • 前提条件
  • 採用されたアプローチ

第2章 エグゼクティブサマリー

• 市場スナップショット：世界の抗てんかん薬市場
• 世界の抗てんかん薬市場：薬剤クラス別（2021年）
• 世界の抗てんかん薬市場：地域別（2021年）
• COVID-19の影響
• 魅力的な投資提案：地域別（2021年）
• 競合分析
  • 主要な抗てんかん薬市場ベンダーの市場ポジショニング
  • 抗てんかん薬市場のベンダーが採用する戦略
  • 主要な業界戦略

第3章 抗てんかん薬市場：ビジネスの見通しと市場力学

• イントロダクション
• 世界の抗てんかん薬の市場価値（2020年～2030年）
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主要な課題
  • 主要な機会
• 促進要因と抑制要因の影響分析
• シーソー分析
• ポーターのファイブフォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係
• PESTEL分析
  • 政治情勢
  • 経済情勢
  • 技術情勢
  • 法的情勢
  • 社会情勢

第4章 抗てんかん薬市場：薬剤クラス別（2020年～2030年）

• 市場概要
• 成長・収益分析：2021年対2030年
• 市場の内訳
  • ヒダントイン誘導体
  • イミノスチルベン
  • 長時間作用型バルビツレート
  • スクシンイミド
  • ベンゾジアゼピン
  • 炭酸脱水酵素阻害薬（CAI）
  • GAMA-ビニール-GABA
  • アミノ酸誘導体
  • 単糖誘導体
  • その他

第5章 北米の抗てんかん薬市場（2020年～2030年）

• 市場概要
• 薬剤クラス別（2020年～2030年）
• 地域別（2020年～2030年）
  • 北米

第6章 英国・EUの抗てんかん薬市場（2020年～2030年）

• 市場概要
• 薬剤クラス別（2020年～2030年）
• 地域別（2020年～2030年）
  • 英国・EU

第7章 アジア太平洋の抗てんかん薬市場（2020年～2030年）

• 市場概要
• 薬剤クラス別（2020年～2030年）
• 地域別（2020年～2030年）
  • アジア太平洋

第8章 ラテンアメリカの抗てんかん薬市場（2020年～2030年）

• 市場概要
• 薬剤クラス別（2020年～2030年）
• 地域別（2020年～2030年）
  • ラテンアメリカ

第9章 中東・アフリカの抗てんかん薬市場（2020年～2030年）

• 市場概要
• 薬剤クラス別（2020年～2030年）
• 地域別（2020年～2030年）
  • 中東・アフリカ

第10章 企業プロファイル

• Abide Therapeutics
• Advicenne Pharma SA
• Alexza Pharmaceuticals
• Argentum Pharmaceuticals
• GlaxoSmithKline（GSK）plc
• GW Pharmaceuticals Plc
• Janssen Pharmaceuticals
• Marinus Pharmaceuticals
• Novartis Pharmaceuticals Corp
• Otsuka Pharmaceuticals
• Pfizer Inc.
• Takeda Pharmaceutical Company Ltd
• UCB Pharma

List of Tables

• TABLE 1 Global Anti-epileptic Drugs Market By Drug Class, 2020-2030, USD (Million)
• TABLE 2 Global Anti-epileptic Drugs Market By Hydantoin derivatives, 2020-2030, USD (Million)
• TABLE 3 Global Anti-epileptic Drugs Market By Iminostilbenes, 2020-2030, USD (Million)
• TABLE 4 Global Anti-epileptic Drugs Market By Long acting barbiturates, 2020-2030, USD (Million)
• TABLE 5 Global Anti-epileptic Drugs Market By Succinimides, 2020-2030, USD (Million)
• TABLE 6 Global Anti-epileptic Drugs Market By Benzodiazepines, 2020-2030, USD (Million)
• TABLE 7 Global Anti-epileptic Drugs Market By Carbonic anhydrase inhibitors (CAI), 2020-2030, USD (Million)
• TABLE 8 Global Anti-epileptic Drugs Market By GAMA- vinyl - GABA, 2020-2030, USD (Million)
• TABLE 9 Global Anti-epileptic Drugs Market By Amino acid derivatives, 2020-2030, USD (Million)
• TABLE 10 Global Anti-epileptic Drugs Market By Monosaccharide derivatives, 2020-2030, USD (Million)
• TABLE 11 North America Anti-epileptic Drugs Market By Drug Class, 2020-2030, USD (Million)
• TABLE 12 North America Anti-epileptic Drugs Market By Hydantoin derivatives, 2020-2030, USD (Million)
• TABLE 13 North America Anti-epileptic Drugs Market By Iminostilbenes, 2020-2030, USD (Million)
• TABLE 14 North America Anti-epileptic Drugs Market By Long acting barbiturates, 2020-2030, USD (Million)
• TABLE 15 North America Anti-epileptic Drugs Market By Succinimides, 2020-2030, USD (Million)
• TABLE 16 North America Anti-epileptic Drugs Market By Benzodiazepines, 2020-2030, USD (Million)
• TABLE 17 North America Anti-epileptic Drugs Market By Carbonic anhydrase inhibitors (CAI), 2020-2030, USD (Million)
• TABLE 18 North America Anti-epileptic Drugs Market By GAMA- vinyl - GABA, 2020-2030, USD (Million)
• TABLE 19 North America Anti-epileptic Drugs Market By Amino acid derivatives, 2020-2030, USD (Million)
• TABLE 20 North America Anti-epileptic Drugs Market By Monosaccharide derivatives, 2020-2030, USD (Million)
• TABLE 21 UK and European Union Anti-epileptic Drugs Market By Drug Class, 2020-2030, USD (Million)
• TABLE 22 UK and European Union Anti-epileptic Drugs Market By Hydantoin derivatives, 2020-2030, USD (Million)
• TABLE 23 UK and European Union Anti-epileptic Drugs Market By Iminostilbenes, 2020-2030, USD (Million)
• TABLE 24 UK and European Union Anti-epileptic Drugs Market By Long acting barbiturates, 2020-2030, USD (Million)
• TABLE 25 UK and European Union Anti-epileptic Drugs Market By Succinimides, 2020-2030, USD (Million)
• TABLE 26 UK and European Union Anti-epileptic Drugs Market By Benzodiazepines, 2020-2030, USD (Million)
• TABLE 27 UK and European Union Anti-epileptic Drugs Market By Carbonic anhydrase inhibitors (CAI), 2020-2030, USD (Million)
• TABLE 28 UK and European Union Anti-epileptic Drugs Market By GAMA- vinyl - GABA, 2020-2030, USD (Million)
• TABLE 29 UK and European Union Anti-epileptic Drugs Market By Amino acid derivatives, 2020-2030, USD (Million)
• TABLE 30 UK and European Union Anti-epileptic Drugs Market By Monosaccharide derivatives, 2020-2030, USD (Million)
• TABLE 31 Asia Pacific Anti-epileptic Drugs Market By Drug Class, 2020-2030, USD (Million)
• TABLE 32 Asia Pacific Anti-epileptic Drugs Market By Hydantoin derivatives, 2020-2030, USD (Million)
• TABLE 33 Asia Pacific Anti-epileptic Drugs Market By Iminostilbenes, 2020-2030, USD (Million)
• TABLE 34 Asia Pacific Anti-epileptic Drugs Market By Long acting barbiturates, 2020-2030, USD (Million)
• TABLE 35 Asia Pacific Anti-epileptic Drugs Market By Succinimides, 2020-2030, USD (Million)
• TABLE 36 Asia Pacific Anti-epileptic Drugs Market By Benzodiazepines, 2020-2030, USD (Million)
• TABLE 37 Asia Pacific Anti-epileptic Drugs Market By Carbonic anhydrase inhibitors (CAI), 2020-2030, USD (Million)
• TABLE 38 Asia Pacific Anti-epileptic Drugs Market By GAMA- vinyl - GABA, 2020-2030, USD (Million)
• TABLE 39 Asia Pacific Anti-epileptic Drugs Market By Amino acid derivatives, 2020-2030, USD (Million)
• TABLE 40 Asia Pacific Anti-epileptic Drugs Market By Monosaccharide derivatives, 2020-2030, USD (Million)
• TABLE 41 Latin America Anti-epileptic Drugs Market By Drug Class, 2020-2030, USD (Million)
• TABLE 42 Latin America Anti-epileptic Drugs Market By Hydantoin derivatives, 2020-2030, USD (Million)
• TABLE 43 Latin America Anti-epileptic Drugs Market By Iminostilbenes, 2020-2030, USD (Million)
• TABLE 44 Latin America Anti-epileptic Drugs Market By Long acting barbiturates, 2020-2030, USD (Million)
• TABLE 45 Latin America Anti-epileptic Drugs Market By Succinimides, 2020-2030, USD (Million)
• TABLE 46 Latin America Anti-epileptic Drugs Market By Benzodiazepines, 2020-2030, USD (Million)
• TABLE 47 Latin America Anti-epileptic Drugs Market By Carbonic anhydrase inhibitors (CAI), 2020-2030, USD (Million)
• TABLE 48 Latin America Anti-epileptic Drugs Market By GAMA- vinyl - GABA, 2020-2030, USD (Million)
• TABLE 49 Latin America Anti-epileptic Drugs Market By Amino acid derivatives, 2020-2030, USD (Million)
• TABLE 50 Latin America Anti-epileptic Drugs Market By Monosaccharide derivatives, 2020-2030, USD (Million)
• TABLE 51 Middle East and Africa Anti-epileptic Drugs Market By Drug Class, 2020-2030, USD (Million)
• TABLE 52 Middle East and Africa Anti-epileptic Drugs Market By Hydantoin derivatives, 2020-2030, USD (Million)
• TABLE 53 Middle East and Africa Anti-epileptic Drugs Market By Iminostilbenes, 2020-2030, USD (Million)
• TABLE 54 Middle East and Africa Anti-epileptic Drugs Market By Long acting barbiturates, 2020-2030, USD (Million)
• TABLE 55 Middle East and Africa Anti-epileptic Drugs Market By Succinimides, 2020-2030, USD (Million)
• TABLE 56 Middle East and Africa Anti-epileptic Drugs Market By Benzodiazepines, 2020-2030, USD (Million)
• TABLE 57 Middle East and Africa Anti-epileptic Drugs Market By Carbonic anhydrase inhibitors (CAI), 2020-2030, USD (Million)
• TABLE 58 Middle East and Africa Anti-epileptic Drugs Market By GAMA- vinyl - GABA, 2020-2030, USD (Million)
• TABLE 59 Middle East and Africa Anti-epileptic Drugs Market By Amino acid derivatives, 2020-2030, USD (Million)
• TABLE 60 Middle East and Africa Anti-epileptic Drugs Market By Monosaccharide derivatives, 2020-2030, USD (Million)

List of Figures

• FIG. 1 Global Anti-epileptic Drugs Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Anti-epileptic Drugs Market: Quality Assurance
• FIG. 5 Global Anti-epileptic Drugs Market, By Drug Class, 2021
• FIG. 6 Global Anti-epileptic Drugs Market, By Geography, 2021
• FIG. 7 Global Anti-epileptic Drugs Market, By Drug Class, 2021 Vs 2030, %
• FIG. 8 U.S. Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 9 Canada Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 10 Rest of North America Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 11 UK Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 12 Germany Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 13 Spain Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 14 Italy Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 15 France Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 16 Rest of Europe Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 17 China Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 18 Japan Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 19 India Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 20 Australia Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 21 South Korea Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 22 Rest of Asia Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 23 Brazil Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 24 Mexico Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 25 Rest of Latin America Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 26 GCC Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 27 Africa Anti-epileptic Drugs Market (US$ Million), 2020 - 2030
• FIG. 28 Rest of Middle East and Africa Anti-epileptic Drugs Market (US$ Million), 2020 - 2030

Epilepsy is a neurological disorder in which patient experiences epileptic seizures. These epileptic seizures are a result of the disturbance in the electrical communication in neurons. Seizures can vary from short period to long episodes of vigorous shaking. Epilepsy can be diagnosed in a patient only after one or more seizure episodes. Patients may have more than one type of seizure and these seizures usually follow the same pattern each time they occur to the patient. Causes of epilepsy include patient's genetics, tumor or brain injuries. Epileptic seizures are of two types, i.e. focal and generalized depending on the affected area of the brain. Symptoms which occur before seizures include nausea, headache, strange feeling and visual loss. Anti-epileptic drugs are used to treat this neurological disorder.

This market analysis report on anti-epileptic drugs market provides a detailed analysis of the market. This report explains key market trends and aids industry leaders in their strategic initiative and decision making. The report provides market value and forecast for the anti-epileptic drugs market.

The scope of the report comprises demarcation of the market in terms of drug class and geographical distribution. The drug class segments are further categorized into hydantoin derivatives, iminostilbenes, long-acting barbiturates, succinimides, benzodiazepines, carbonic anhydrase inhibitors (CAI), GAMA- vinyl - GABA, amino acid derivatives, monosaccharide derivatives, and others. Others include valproic acid derivatives, deoxy barbiturate, phenyltriazine, nicotinic acid derivatives and sulphonamide derivatives. Each segment is analyzed considering market drivers and restraints for the market value of anti-epileptic drugs market. CAGRs are provided for the forecast year 2022-2030 for each segment.

This report provides key insights about the global anti-epileptic drugs market including market drivers & restraints, key trends, opportunities, and regional outlook. Analysis tools such as Porter's five forces along with competitive landscape analysis are also incorporated in this report. Leading players in the global anti-epileptic market are also profiled in this report. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.

A complete description is also presented regarding the market dynamics in the report to understand and anticipate the trends in the market. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also incorporates the company profiling of the major market players which hold prominent position in the anti-epileptic drugs market globally. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.

Anti-epileptic drugs are classified based on the drug class. Each drug class has different mechanism of action for the treatment of epilepsy. Due to difference in mechanism of action, prescription of the drug depends on the type of seizures occurring to the patients. Most of the drugs are used as monotherapy and for partial onset seizures. Succinimides, hydantoin derivatives and benzodiazepines are mostly preferred by the doctorsVimpat, Fycompa, Lacosamide and Retigabine are some of the ant-epileptic drugs preferred by the physicians.

Increasing awareness about treatment with anti-epileptic drugs, patent expiration and approval of pipeline products are the factors responsible for the market growth. The global anti-epileptic drugs market is emerging at considerable pace because of high prevalence of epilepsy and more research and development activities involved.

Geographically, the global anti-epileptic drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.

According to the estimation for the year 2020, North America dominated the global anti-epileptic drugs market by accounting major market share. In terms of market share, North America is followed by Europe. Increased healthcare expenditure, government initiatives and approval of new drugs are the prime factors regulating the market in these regions. For instance, a few years back, Eisai Co. Ltd. has launched Fycompa in Americas and Europe. Other factors for the market growth in this region include high prevalence of epilepsy and presence of treatment options in the region. According to the research, there are around 2.5 million cases of epilepsy in the U.S. and around 15,000 new cases of epilepsy are diagnosed each year in Canada. In terms of market value, Europe is followed by Asia Pacific. Due to the high prevalence of epilepsy in China and India and increased awareness of epilepsy are some of the major factors responsible for anti-epileptic drugs market growth.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anti-epileptic Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Anti-epileptic Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Hydantoin derivatives

Phenytoin

Fosphenytoin

Iminostilbenes

Carbamazepine

Oxcarbazepine

Long acting barbiturates

Phenobarbitone

Methobarbitone

Succinimides

Ethosuximide

Methsuximide

Phensuximide

Benzodiazepines

Clonazepam

Nitrazepam

Diazepam

Carbonic anhydrase inhibitors (CAI)

Acetazolamide

Sulthiame

GAMA- vinyl - GABA

Vigabatrin

Amino acid derivatives

GABA pentin

Monosaccharide derivatives

Topiramate

Others

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Anti-epileptic Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Anti-epileptic Drugs market?

Which is the largest regional market for Anti-epileptic Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Anti-epileptic Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Anti-epileptic Drugs market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Anti-epileptic Drugs Market
• 2.2. Global Anti-epileptic Drugs Market, By Drug Class, 2021 (US$ Million)
• 2.3. Global Anti-epileptic Drugs Market, By Geography, 2021 (US$ Million)
• 2.4. Impact of Covid 19
• 2.5. Attractive Investment Proposition by Geography, 2021
• 2.6. Competitive Analysis
  • 2.6.1. Market Positioning of Key Anti-epileptic Drugs Market Vendors
  • 2.6.2. Strategies Adopted by Anti-epileptic Drugs Market Vendors
  • 2.6.3. Key Industry Strategies

3. Anti-epileptic Drugs Market: Business Outlook & Market Dynamics

• 3.1. Introduction
• 3.2. Global Anti-epileptic Drugs Market Value, 2020 - 2030, (US$ Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers
  • 3.3.2. Market Restraints
  • 3.3.3. Key Challenges
  • 3.3.4. Key Opportunities
• 3.4. Impact Analysis of Drivers and Restraints
• 3.5. See-Saw Analysis
• 3.6. Porter's Five Force Model
  • 3.6.1. Supplier Power
  • 3.6.2. Buyer Power
  • 3.6.3. Threat Of Substitutes
  • 3.6.4. Threat Of New Entrants
  • 3.6.5. Competitive Rivalry
• 3.7. PESTEL Analysis
  • 3.7.1. Political Landscape
  • 3.7.2. Economic Landscape
  • 3.7.3. Technology Landscape
  • 3.7.4. Legal Landscape
  • 3.7.5. Social Landscape

4. Anti-epileptic Drugs Market: By Drug Class, 2020-2030, USD (Million)

• 4.1. Market Overview
• 4.2. Growth & Revenue Analysis: 2021 Versus 2030
• 4.3. Market Segmentation
  • 4.3.1. Hydantoin derivatives
    • 4.3.1.1. Phenytoin
    • 4.3.1.2. Fosphenytoin
  • 4.3.2. Iminostilbenes
    • 4.3.2.1. Carbamazepine
    • 4.3.2.2. Oxcarbazepine
  • 4.3.3. Long acting barbiturates
    • 4.3.3.1. Phenobarbitone
    • 4.3.3.2. Methobarbitone
  • 4.3.4. Succinimides
    • 4.3.4.1. Ethosuximide
    • 4.3.4.2. Methsuximide
    • 4.3.4.3. Phensuximide
  • 4.3.5. Benzodiazepines
    • 4.3.5.1. Clonazepam
    • 4.3.5.2. Nitrazepam
    • 4.3.5.3. Diazepam
  • 4.3.6. Carbonic anhydrase inhibitors (CAI)
    • 4.3.6.1. Acetazolamide
    • 4.3.6.2. Sulthiame
  • 4.3.7. GAMA- vinyl - GABA
    • 4.3.7.1. Vigabatrin
  • 4.3.8. Amino acid derivatives
    • 4.3.8.1. GABA pentin
  • 4.3.9. Monosaccharide derivatives
    • 4.3.9.1. Topiramate
  • 4.3.10. Others

5. North America Anti-epileptic Drugs Market, 2020-2030, USD (Million)

• 5.1. Market Overview
• 5.2. Anti-epileptic Drugs Market: By Drug Class, 2020-2030, USD (Million)
• 5.3.Anti-epileptic Drugs Market: By Region, 2020-2030, USD (Million)
  • 5.3.1.North America
    • 5.3.1.1. U.S.
    • 5.3.1.2. Canada
    • 5.3.1.3. Rest of North America

6. UK and European Union Anti-epileptic Drugs Market, 2020-2030, USD (Million)

• 6.1. Market Overview
• 6.2. Anti-epileptic Drugs Market: By Drug Class, 2020-2030, USD (Million)
• 6.3.Anti-epileptic Drugs Market: By Region, 2020-2030, USD (Million)
  • 6.3.1.UK and European Union
    • 6.3.1.1. UK
    • 6.3.1.2. Germany
    • 6.3.1.3. Spain
    • 6.3.1.4. Italy
    • 6.3.1.5. France
    • 6.3.1.6. Rest of Europe

7. Asia Pacific Anti-epileptic Drugs Market, 2020-2030, USD (Million)

• 7.1. Market Overview
• 7.2. Anti-epileptic Drugs Market: By Drug Class, 2020-2030, USD (Million)
• 7.3.Anti-epileptic Drugs Market: By Region, 2020-2030, USD (Million)
  • 7.3.1.Asia Pacific
    • 7.3.1.1. China
    • 7.3.1.2. Japan
    • 7.3.1.3. India
    • 7.3.1.4. Australia
    • 7.3.1.5. South Korea
    • 7.3.1.6. Rest of Asia Pacific

8. Latin America Anti-epileptic Drugs Market, 2020-2030, USD (Million)

• 8.1. Market Overview
• 8.2. Anti-epileptic Drugs Market: By Drug Class, 2020-2030, USD (Million)
• 8.3.Anti-epileptic Drugs Market: By Region, 2020-2030, USD (Million)
  • 8.3.1.Latin America
    • 8.3.1.1. Brazil
    • 8.3.1.2. Mexico
    • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Anti-epileptic Drugs Market, 2020-2030, USD (Million)

• 9.1. Market Overview
• 9.2. Anti-epileptic Drugs Market: By Drug Class, 2020-2030, USD (Million)
• 9.3.Anti-epileptic Drugs Market: By Region, 2020-2030, USD (Million)
  • 9.3.1.Middle East and Africa
    • 9.3.1.1. GCC
    • 9.3.1.2. Africa
    • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

• 10.1. Abide Therapeutics
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Portfolio
  • 10.1.4. Strategic Initiatives
• 10.2. Advicenne Pharma SA
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Portfolio
  • 10.2.4. Strategic Initiatives
• 10.3. Alexza Pharmaceuticals
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Portfolio
  • 10.3.4. Strategic Initiatives
• 10.4. Argentum Pharmaceuticals
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Portfolio
  • 10.4.4. Strategic Initiatives
• 10.5. GlaxoSmithKline (GSK) plc
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Portfolio
  • 10.5.4. Strategic Initiatives
• 10.6. GW Pharmaceuticals Plc
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Portfolio
  • 10.6.4. Strategic Initiatives
• 10.7. Janssen Pharmaceuticals
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Portfolio
  • 10.7.4. Strategic Initiatives
• 10.8. Marinus Pharmaceuticals
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Portfolio
  • 10.8.4. Strategic Initiatives
• 10.9. Novartis Pharmaceuticals Corp
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Portfolio
  • 10.9.4. Strategic Initiatives
• 10.10. Otsuka Pharmaceuticals
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Portfolio
  • 10.10.4. Strategic Initiatives
• 10.11. Pfizer Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Portfolio
  • 10.11.4. Strategic Initiatives
• 10.12. Takeda Pharmaceutical Company Ltd
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Portfolio
  • 10.12.4. Strategic Initiatives
• 10.13. UCB Pharma
  • 10.13.1. Company Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Portfolio
  • 10.13.4. Strategic Initiatives